欧洲疫苗佐剂市场预测至 2030 年 – 区域分析 – 按佐剂类别(矿物盐佐剂、乳液佐剂、脂质体佐剂等)和类型(人用疫苗佐剂和兽用疫苗佐剂)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 93    |    Report Code: BMIRE00031104    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Vaccine Adjuvants Market
2022 年欧洲疫苗佐剂市场价值为 7.405 亿美元,预计到 2030 年将达到 20.5105 亿美元;预计 2022 年至 2030 年的复合年增长率为 13.6%。
兽用疫苗佐剂的批准推动欧洲疫苗佐剂市场发展

为动物接种常见疾病疫苗仍然是全球范围内防止动物养殖中传染病造成经济和其他损失最成功的方法。兽用疫苗佐剂的监管批准正在增加,制造商越来越注重开发具有更高功效和稳定性的疫苗。Montanide 是已知的兽用疫苗佐剂之一。Montanide 佐剂系列基于三种核心技术——乳液、微乳液和聚合物。因此,兽用疫苗佐剂审批数量的激增加速了疫苗佐剂的整体市场增长。
欧洲疫苗佐剂市场概览

欧洲疫苗佐剂市场已细分为德国、英国、法国、意大利、西班牙和欧洲其他地区。一些顶级疫苗制造商在德国设有办事处。2022 年 12 月,赢创推出了一种名为 PhytoSquene 的植物基角鲨烯,以提高疫苗效力。它是一种适用于疫苗和其他药物应用的非动物衍生物。PhytoSquene 是市场上第一个已知的苋菜油衍生角鲨烯,用于非肠道用药的佐剂。赢创的这一最新创新旨在为市场提供可持续的非动物衍生解决方案。 2021 年,赢创推出了药用级和植物源胆固醇“PhytoChol”。
欧洲疫苗佐剂市场收入及 2030 年预测(百万美元)

欧洲疫苗佐剂市场细分

欧洲疫苗佐剂市场分为佐剂类别、类型和国家。

根据佐剂类别,欧洲疫苗佐剂市场细分为矿物盐佐剂、乳剂佐剂、脂质体佐剂等。矿物盐佐剂部分在 2022 年占据欧洲疫苗佐剂市场份额的最大份额。

按类型,欧洲疫苗佐剂市场分为人用疫苗佐剂和兽用疫苗佐剂。2022 年人用疫苗佐剂部分在欧洲疫苗佐剂市场中占有较大份额。 2022。

按国家/地区划分,欧洲疫苗佐剂市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。2022 年,德国占据了欧洲疫苗佐剂市场份额的主导地位。

Croda International Plc;CSL Ltd;Dynavax Technologies Corp;GSK Plc;InvivoGen SAS;Novavax Inc.;Phibro Animal Health Corp;Seppic SA;和 SPI Pharma Inc 是欧洲疫苗佐剂市场的一些领先公司。

Europe Vaccine Adjuvants Strategic Insights

Strategic insights for Europe Vaccine Adjuvants involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-vaccine-adjuvants-market-strategic-framework.webp
Get more information on this report

Europe Vaccine Adjuvants Report Scope

Report Attribute Details
Market size in 2022 US$ 740.50 Million
Market Size by 2030 US$ 2,051.05 Million
Global CAGR (2022 - 2030) 13.6%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 佐剂类
  • 矿物盐佐剂
  • 乳剂佐剂
  • 脂质体佐剂
By 类型
  • 人用疫苗佐剂
  • 兽用疫苗佐剂
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
  • Get more information on this report

    Europe Vaccine Adjuvants Regional Insights

    The regional scope of Europe Vaccine Adjuvants refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-vaccine-adjuvants-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Vaccine Adjuvants Market

    • SPI Pharma Inc
    • GSK Plc
    • CSL Ltd
    • Seppic SA
    • Dynavax Technologies Corp
    • InvivoGen SAS
    • Croda International Plc
    • Novavax Inc
    • Phibro Animal Health Corp
    Frequently Asked Questions
    How big is the Europe Vaccine Adjuvants Market?

    The Europe Vaccine Adjuvants Market is valued at US$ 740.50 Million in 2022, it is projected to reach US$ 2,051.05 Million by 2030.

    What is the CAGR for Europe Vaccine Adjuvants Market by (2022 - 2030)?

    As per our report Europe Vaccine Adjuvants Market, the market size is valued at US$ 740.50 Million in 2022, projecting it to reach US$ 2,051.05 Million by 2030. This translates to a CAGR of approximately 13.6% during the forecast period.

    What segments are covered in this report?

    The Europe Vaccine Adjuvants Market report typically cover these key segments-

  • 佐剂类 (矿物盐佐剂, 乳剂佐剂, 脂质体佐剂)
  • 类型 (人用疫苗佐剂, 兽用疫苗佐剂)
  • What is the historic period, base year, and forecast period taken for Europe Vaccine Adjuvants Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Vaccine Adjuvants Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Vaccine Adjuvants Market?

    The Europe Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
  • Who should buy this report?

    The Europe Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.